Xilio Therapeutics, Inc.
XLO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001840233
No open-market purchases or sales by Xilio Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $32.6M in total; no superinvestor holds it.
Q3 2022 vs. Q2 2022
How the institutions holding Xilio Therapeutics, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 33 | 29 | −4 |
| Shares | 17.9M | 16.6M | −1.27M (−7.1%) |
| Value | $52.2M | $48.3M | −$3.89M (−7.4%) |
New holders (3)
Institutions that held Xilio Therapeutics, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Octagon Capital Advisors LP | 2,425,000 | $7.06M | 1.22% |
| Bridgeway Capital Management, LLC | 76,081 | $221.0K | 0.01% |
| Nwam LLC | 10,000 | $29.0K | 0.00% |
Sold out (7)
Institutions that held Xilio Therapeutics, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Deerfield Management Company, L.P. (Series C) | 2,078,692 | $6.07M |
| Ra Capital Management, L.P. | 1,649,711 | $4.82M |
| Norges Bank | 121,887 | $355.9K |
| Bailard, Inc. | 36,632 | $107.0K |
| New York State Common Retirement Fund | 64 | $0 |
| Credit Suisse AG | 4 | $0 |
| Citigroup Inc | 67 | $0 |